Illumina

Illumina
Name	Illumina
Type	Public
Industry	Biotechnology
Founded	1998
Founders	David Walt, John Stuelpnagel, Anthony Czarnik, Mark Chee, Jay Flatley
Headquarters	San Diego, California, United States
Key people	Jay Flatley, Francis deSouza
Products	DNA sequencing systems, genotyping arrays, consumables
Revenue	(varies)

Illumina is a biotechnology company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and function. The company is known for high-throughput DNA sequencing platforms, genotyping arrays, and associated consumables used across biomedical research, clinical diagnostics, agriculture, and forensics. Illumina's instruments and services have been adopted by academic institutions, private companies, and government agencies worldwide.

History

Illumina was founded in 1998 by David Walt, John Stuelpnagel, Anthony Czarnik, Mark Chee, and Jay Flatley during a period of rapid development in genomics linked to the Human Genome Project, the rise of companies like Applied Biosystems, and advances from universities such as Harvard University and Cambridge University. Early financing involved venture capital firms and collaborations with firms such as SBC Communications and strategic partnerships with research centers including the Broad Institute and Sanger Institute. The company expanded through acquisitions, including Solexa in 2007, which provided sequencing-by-synthesis technology, and later purchases that echoed consolidation moves by contemporaries like Roche and Thermo Fisher Scientific. Leadership transitions included chief executives Jay Flatley and Francis deSouza, and growth paralleled major projects such as the 1000 Genomes Project and initiatives at institutions like Wellcome Trust and National Institutes of Health.

Technology and Products

Illumina commercialized sequencing-by-synthesis technology derived from Solexa and competing approaches from companies such as Roche 454 and Pacific Biosciences. Core products include high-throughput platforms comparable to systems from Oxford Nanopore Technologies and BGI Group, and microarray products analogous to offerings from Affymetrix (now part of Thermo Fisher Scientific). Instrument families include benchtop sequencers for laboratories at the scale of Massachusetts Institute of Technology labs, as well as high-output instruments used by entities like Genomics England and large pharmaceutical companies such as Pfizer and Novartis. Consumables and software integrate with bioinformatics pipelines used alongside tools from Broad Institute's GATK, European Bioinformatics Institute, and databases maintained by National Center for Biotechnology Information.

Applications

Illumina systems have been applied in projects at academic centers including Stanford University, Yale University, University of California, San Diego, and in clinical contexts at hospitals such as Mayo Clinic and Johns Hopkins Hospital. Uses encompass whole-genome sequencing in population studies like UK Biobank and All of Us Research Program, cancer genomics initiatives at institutions such as Memorial Sloan Kettering Cancer Center, infectious disease surveillance coordinated with agencies like Centers for Disease Control and Prevention and World Health Organization, agricultural genomics with firms like Monsanto (now Bayer), and forensic applications in law enforcement collaborations with agencies such as the FBI. Illumina technology underpins translational research in partnerships with pharmaceutical companies including GlaxoSmithKline and Roche.

Business and Market

Illumina operates in a market populated by competitors and partners such as Thermo Fisher Scientific, Oxford Nanopore Technologies, BGI Group, and PacBio. The company has engaged with global customers including national sequencing centers at European Molecular Biology Laboratory and commercial genomics service providers like 23andMe and Ancestry.com. Strategic business moves have included mergers and acquisitions reflective of trends seen with Agilent Technologies and Qiagen. Illumina's market position influenced financing, investor relations with entities such as Goldman Sachs and Morgan Stanley, and scrutiny from regulatory bodies like the Federal Trade Commission and the European Commission.

Research and Collaborations

Illumina collaborates with academic institutions such as Harvard University, MIT, Stanford University, and University of Cambridge, research consortia including the Human Genome Project legacy groups, and public health agencies like Centers for Disease Control and Prevention and National Institutes of Health. Collaborative programs include support for population-scale sequencing efforts like 1000 Genomes Project, UK Biobank, and disease-focused alliances with Cancer Research UK and American Cancer Society. Partnerships with technology firms and data platforms intersect with companies like Google for cloud bioinformatics, alliances with Microsoft for enterprise solutions, and integration with databases maintained by European Bioinformatics Institute and National Center for Biotechnology Information.

Controversies and Legal Issues

Illumina has been involved in legal and regulatory disputes reminiscent of litigation in the life sciences sector involving firms like Thermo Fisher Scientific and Roche. Notable issues have included competition-related investigations by the Federal Trade Commission and reviews by the European Commission, contractual disputes with service providers and customers including BGI Group and others, and litigation concerning intellectual property overlaps akin to cases in which Pacific Biosciences and Affymetrix were parties. The company has faced scrutiny over pricing and market concentration similar to debates involving Amazon and Google in technology markets, and ethical discussions around genomic data sharing that involve stakeholders such as Wellcome Trust and National Institutes of Health.

Category:Biotechnology companies Category:Genomics